AU767394C - Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use - Google Patents
Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic useInfo
- Publication number
- AU767394C AU767394C AU29066/01A AU2906601A AU767394C AU 767394 C AU767394 C AU 767394C AU 29066/01 A AU29066/01 A AU 29066/01A AU 2906601 A AU2906601 A AU 2906601A AU 767394 C AU767394 C AU 767394C
- Authority
- AU
- Australia
- Prior art keywords
- daunorubicin
- modified
- doxorubicin
- daunorubicins
- carbon atoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 229940127089 cytotoxic agent Drugs 0.000 title claims abstract description 25
- 239000002254 cytotoxic agent Substances 0.000 title claims abstract description 25
- 231100000599 cytotoxic agent Toxicity 0.000 title claims abstract description 25
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 9
- 239000011230 binding agent Substances 0.000 claims abstract description 37
- 125000005647 linker group Chemical group 0.000 claims abstract description 35
- 238000000034 method Methods 0.000 claims abstract description 31
- 239000000203 mixture Substances 0.000 claims abstract description 6
- 239000003937 drug carrier Substances 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims description 26
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 23
- 125000004432 carbon atom Chemical group C* 0.000 claims description 17
- 125000000217 alkyl group Chemical group 0.000 claims description 14
- 125000000623 heterocyclic group Chemical group 0.000 claims description 5
- 125000003107 substituted aryl group Chemical group 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 abstract description 69
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 abstract description 69
- 229960000975 daunorubicin Drugs 0.000 abstract description 69
- 230000001472 cytotoxic effect Effects 0.000 abstract description 13
- 231100000433 cytotoxic Toxicity 0.000 abstract description 12
- 229910052717 sulfur Inorganic materials 0.000 abstract description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 107
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 103
- 239000000562 conjugate Substances 0.000 description 53
- 229960004679 doxorubicin Drugs 0.000 description 38
- 239000003814 drug Substances 0.000 description 34
- 229940079593 drug Drugs 0.000 description 33
- 150000003573 thiols Chemical class 0.000 description 23
- 206010028980 Neoplasm Diseases 0.000 description 19
- 201000011510 cancer Diseases 0.000 description 16
- 238000011282 treatment Methods 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 13
- 230000003013 cytotoxicity Effects 0.000 description 12
- 231100000135 cytotoxicity Toxicity 0.000 description 12
- 239000000427 antigen Substances 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 239000002253 acid Substances 0.000 description 9
- 230000021615 conjugation Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 125000003277 amino group Chemical group 0.000 description 7
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 125000001424 substituent group Chemical group 0.000 description 7
- JVWLUVNSQYXYBE-UHFFFAOYSA-N Ribitol Natural products OCC(C)C(O)C(O)CO JVWLUVNSQYXYBE-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 125000002228 disulfide group Chemical group 0.000 description 6
- 125000005414 dithiopyridyl group Chemical group 0.000 description 6
- 208000024908 graft versus host disease Diseases 0.000 description 6
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 6
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 6
- -1 tert.-butyl Chemical group 0.000 description 6
- INAUWOVKEZHHDM-PEDBPRJASA-N (7s,9s)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7-[(2r,4s,5s,6s)-5-hydroxy-6-methyl-4-morpholin-4-yloxan-2-yl]oxy-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.N1([C@H]2C[C@@H](O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCOCC1 INAUWOVKEZHHDM-PEDBPRJASA-N 0.000 description 5
- 208000009329 Graft vs Host Disease Diseases 0.000 description 5
- 206010052779 Transplant rejections Diseases 0.000 description 5
- 230000001464 adherent effect Effects 0.000 description 5
- 239000003098 androgen Substances 0.000 description 5
- 239000000611 antibody drug conjugate Substances 0.000 description 5
- 210000001185 bone marrow Anatomy 0.000 description 5
- 238000002523 gelfiltration Methods 0.000 description 5
- 229940127121 immunoconjugate Drugs 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 125000003396 thiol group Chemical group [H]S* 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- HJVJLAOFAYPFHL-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-pyridin-2-ylpropanedithioate Chemical compound C=1C=CC=NC=1C(C)C(=S)SN1C(=O)CCC1=O HJVJLAOFAYPFHL-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 4
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 229920005654 Sephadex Polymers 0.000 description 4
- 239000012507 Sephadex™ Substances 0.000 description 4
- 229940049595 antibody-drug conjugate Drugs 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 231100000263 cytotoxicity test Toxicity 0.000 description 4
- 229940011871 estrogen Drugs 0.000 description 4
- 239000000262 estrogen Substances 0.000 description 4
- 239000012894 fetal calf serum Substances 0.000 description 4
- 235000019152 folic acid Nutrition 0.000 description 4
- 239000011724 folic acid Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 235000019833 protease Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- GTBCXYYVWHFQRS-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(pyridin-2-yldisulfanyl)pentanoate Chemical compound C=1C=CC=NC=1SSC(C)CCC(=O)ON1C(=O)CCC1=O GTBCXYYVWHFQRS-UHFFFAOYSA-N 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000011691 Burkitt lymphomas Diseases 0.000 description 3
- ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical compound N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 description 3
- 108090000371 Esterases Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 229930182816 L-glutamine Natural products 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 231100000050 cytotoxic potential Toxicity 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 150000002009 diols Chemical class 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000013213 extrapolation Methods 0.000 description 3
- 229960000304 folic acid Drugs 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 description 3
- 150000003568 thioethers Chemical class 0.000 description 3
- GKSPIZSKQWTXQG-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[1-(pyridin-2-yldisulfanyl)ethyl]benzoate Chemical compound C=1C=C(C(=O)ON2C(CCC2=O)=O)C=CC=1C(C)SSC1=CC=CC=N1 GKSPIZSKQWTXQG-UHFFFAOYSA-N 0.000 description 2
- JYWKEVKEKOTYEX-UHFFFAOYSA-N 2,6-dibromo-4-chloroiminocyclohexa-2,5-dien-1-one Chemical compound ClN=C1C=C(Br)C(=O)C(Br)=C1 JYWKEVKEKOTYEX-UHFFFAOYSA-N 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102400001368 Epidermal growth factor Human genes 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 102000011923 Thyrotropin Human genes 0.000 description 2
- 108010061174 Thyrotropin Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 description 2
- 229940045799 anthracyclines and related substance Drugs 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000009643 clonogenic assay Methods 0.000 description 2
- 231100000096 clonogenic assay Toxicity 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 229940051026 immunotoxin Drugs 0.000 description 2
- 239000002596 immunotoxin Substances 0.000 description 2
- 230000002637 immunotoxin Effects 0.000 description 2
- 231100000608 immunotoxin Toxicity 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000002132 lysosomal effect Effects 0.000 description 2
- 239000007758 minimum essential medium Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 2
- 239000008057 potassium phosphate buffer Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 125000000101 thioether group Chemical group 0.000 description 2
- 125000005413 thiopyridyl group Chemical group 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 239000012581 transferrin Substances 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- OGNMVIPRPYCXQN-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 1-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexane-1-carboxylate Chemical compound C1CCCCC1(CN1C(C=CC1=O)=O)C(=O)ON1C(=O)CCC1=O OGNMVIPRPYCXQN-UHFFFAOYSA-N 0.000 description 1
- VRDGQQTWSGDXCU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-iodoacetate Chemical compound ICC(=O)ON1C(=O)CCC1=O VRDGQQTWSGDXCU-UHFFFAOYSA-N 0.000 description 1
- KQRHTCDQWJLLME-XUXIUFHCSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-aminopropanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)N KQRHTCDQWJLLME-XUXIUFHCSA-N 0.000 description 1
- AUXMWYRZQPIXCC-KNIFDHDWSA-N (2s)-2-amino-4-methylpentanoic acid;(2s)-2-aminopropanoic acid Chemical compound C[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O AUXMWYRZQPIXCC-KNIFDHDWSA-N 0.000 description 1
- MWWSFMDVAYGXBV-MYPASOLCSA-N (7r,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-MYPASOLCSA-N 0.000 description 1
- 239000001124 (E)-prop-1-ene-1,2,3-tricarboxylic acid Substances 0.000 description 1
- XZNGUVQDFJHPLU-UHFFFAOYSA-N 1,3-dibromobutane Chemical compound CC(Br)CCBr XZNGUVQDFJHPLU-UHFFFAOYSA-N 0.000 description 1
- MJNWNFXAPAAWLX-UHFFFAOYSA-N 1-(2,5-dioxopyrrolidin-1-yl)-4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexane-1-carboxylic acid Chemical compound C1CC(C(=O)O)(N2C(CCC2=O)=O)CCC1CN1C(=O)C=CC1=O MJNWNFXAPAAWLX-UHFFFAOYSA-N 0.000 description 1
- DIYPCWKHSODVAP-UHFFFAOYSA-N 1-[3-(2,5-dioxopyrrol-1-yl)benzoyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1=CC=CC(N2C(C=CC2=O)=O)=C1 DIYPCWKHSODVAP-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- YMHOBZXQZVXHBM-UHFFFAOYSA-N 2,5-dimethoxy-4-bromophenethylamine Chemical compound COC1=CC(CCN)=C(OC)C=C1Br YMHOBZXQZVXHBM-UHFFFAOYSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- DJBRKGZFUXKLKO-UHFFFAOYSA-N 3-(pyridin-2-yldisulfanyl)propanoic acid Chemical compound OC(=O)CCSSC1=CC=CC=N1 DJBRKGZFUXKLKO-UHFFFAOYSA-N 0.000 description 1
- JWUDANXWFVKRQT-UHFFFAOYSA-N 3-phenylpropanedithioic acid Chemical compound SC(=S)CCC1=CC=CC=C1 JWUDANXWFVKRQT-UHFFFAOYSA-N 0.000 description 1
- QLEJBGASEYPDDG-UHFFFAOYSA-N 4-(pyridin-2-yldisulfanyl)pentanehydrazide Chemical compound NNC(=O)CCC(C)SSC1=CC=CC=N1 QLEJBGASEYPDDG-UHFFFAOYSA-N 0.000 description 1
- OOUPHXWHXYLQBK-UHFFFAOYSA-N 4-(pyridin-2-yldisulfanyl)pentanoic acid Chemical compound OC(=O)CCC(C)SSC1=CC=CC=N1 OOUPHXWHXYLQBK-UHFFFAOYSA-N 0.000 description 1
- LBILFEKNFGGWDY-UHFFFAOYSA-N 4-morpholin-4-yloxymorpholine Chemical class C1COCCN1ON1CCOCC1 LBILFEKNFGGWDY-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000036832 Adenocarcinoma of ovary Diseases 0.000 description 1
- 208000004881 Amebiasis Diseases 0.000 description 1
- 206010001980 Amoebiasis Diseases 0.000 description 1
- QADHLRWLCPCEKT-UHFFFAOYSA-N Androstenediol Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)O)C4C3CC=C21 QADHLRWLCPCEKT-UHFFFAOYSA-N 0.000 description 1
- 206010048396 Bone marrow transplant rejection Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 235000005612 Grewia tenax Nutrition 0.000 description 1
- 244000041633 Grewia tenax Species 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 101000573199 Homo sapiens Protein PML Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- LSPYFSHXDAYVDI-SRVKXCTJSA-N Leu-Ala-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC(C)C LSPYFSHXDAYVDI-SRVKXCTJSA-N 0.000 description 1
- 206010024715 Liver transplant rejection Diseases 0.000 description 1
- 206010051604 Lung transplant rejection Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061328 Ovarian epithelial cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 241001499740 Plantago alpina Species 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- XYONNSVDNIRXKZ-UHFFFAOYSA-N S-methyl methanethiosulfonate Chemical compound CSS(C)(=O)=O XYONNSVDNIRXKZ-UHFFFAOYSA-N 0.000 description 1
- 241000724762 Salmonella phage 5 Species 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102000007238 Transferrin Receptors Human genes 0.000 description 1
- 108010033576 Transferrin Receptors Proteins 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- 102400001320 Transforming growth factor alpha Human genes 0.000 description 1
- 241000545067 Venus Species 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229940091181 aconitic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 201000011186 acute T cell leukemia Diseases 0.000 description 1
- 238000004115 adherent culture Methods 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 108010054982 alanyl-leucyl-alanyl-leucine Proteins 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 229940094957 androgens and estrogen Drugs 0.000 description 1
- QADHLRWLCPCEKT-LOVVWNRFSA-N androst-5-ene-3beta,17beta-diol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC=C21 QADHLRWLCPCEKT-LOVVWNRFSA-N 0.000 description 1
- 229950009148 androstenediol Drugs 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000003127 anti-melanomic effect Effects 0.000 description 1
- UOWVMDUEMSNCAV-UHFFFAOYSA-N antibiotic cc 1065 Chemical compound N1C=2C(OC)=C(O)C=3N(C(N)=O)CCC=3C=2C=C1C(=O)N1CCC(C=2C=3)=C1C(O)=C(OC)C=2NC=3C(=O)N1CC2CC22C1=CC(=O)C1=C2C(C)=CN1 UOWVMDUEMSNCAV-UHFFFAOYSA-N 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003972 antineoplastic antibiotic Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 150000001504 aryl thiols Chemical class 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- BPOPGHPHBCLJOK-UHFFFAOYSA-N butanedithioic acid Chemical compound CCCC(S)=S BPOPGHPHBCLJOK-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 1
- 229930195731 calicheamicin Natural products 0.000 description 1
- 230000003327 cancerostatic effect Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical class NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 239000003687 estradiol congener Substances 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- 102000006815 folate receptor Human genes 0.000 description 1
- 108020005243 folate receptor Proteins 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 201000006592 giardiasis Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 102000054896 human PML Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 238000013415 human tumor xenograft model Methods 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229940125645 monoclonal antibody drug Drugs 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 208000013371 ovarian adenocarcinoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 201000006588 ovary adenocarcinoma Diseases 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000036281 parasite infection Effects 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000000886 photobiology Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 231100000654 protein toxin Toxicity 0.000 description 1
- FFISLTWEISOMFC-UHFFFAOYSA-N pyridin-2-yl propanedithioate Chemical compound CCC(=S)SC1=CC=CC=N1 FFISLTWEISOMFC-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 201000004409 schistosomiasis Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 229960000874 thyrotropin Drugs 0.000 description 1
- 230000001748 thyrotropin Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17349799P | 1999-12-29 | 1999-12-29 | |
| US60/173497 | 1999-12-29 | ||
| PCT/US2000/033276 WO2001049698A1 (en) | 1999-12-29 | 2000-12-19 | Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2906601A AU2906601A (en) | 2001-07-16 |
| AU767394B2 AU767394B2 (en) | 2003-11-06 |
| AU767394C true AU767394C (en) | 2005-04-21 |
Family
ID=22632307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU29066/01A Ceased AU767394C (en) | 1999-12-29 | 2000-12-19 | Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6630579B2 (https=) |
| EP (1) | EP1242438B1 (https=) |
| JP (1) | JP2003531821A (https=) |
| AT (1) | ATE344801T1 (https=) |
| AU (1) | AU767394C (https=) |
| CA (1) | CA2395660A1 (https=) |
| DE (1) | DE60031793T2 (https=) |
| DK (1) | DK1242438T3 (https=) |
| ES (1) | ES2274823T3 (https=) |
| NZ (1) | NZ518764A (https=) |
| PT (1) | PT1242438E (https=) |
| WO (1) | WO2001049698A1 (https=) |
Families Citing this family (393)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040028686A1 (en) * | 2001-06-28 | 2004-02-12 | Faulk Ward Page | Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplated organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer |
| US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
| EP1392359B2 (en) | 2001-05-11 | 2013-03-13 | Ludwig Institute for Cancer Research Ltd. | Specific binding proteins and uses thereof |
| US7129261B2 (en) | 2001-05-31 | 2006-10-31 | Medarex, Inc. | Cytotoxic agents |
| US20060198882A1 (en) * | 2003-03-21 | 2006-09-07 | Yechezkel Barenholz | Stable liposomes or micelles comprising a sphinolipid and a peg-lipopolymer |
| KR101424624B1 (ko) | 2003-05-14 | 2014-07-31 | 이뮤노젠 아이엔씨 | 약물 콘쥬게이트 조성물 |
| WO2005042002A2 (en) * | 2003-10-30 | 2005-05-12 | Entelos, Inc. | Treatment of rhematoid arthritis with flip antagonists |
| US20070287680A1 (en) * | 2004-05-10 | 2007-12-13 | University Of Utah Research Foundation | Combined Active and Passive Targeting of Biologically Active Agents |
| RU2402548C2 (ru) | 2004-05-19 | 2010-10-27 | Медарекс, Инк. | Химические линкеры и их конъюгаты |
| JP4806680B2 (ja) | 2004-05-19 | 2011-11-02 | メダレックス インコーポレイテッド | 自己犠牲リンカー及び薬剤複合体 |
| EP1817004A2 (en) * | 2004-11-15 | 2007-08-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Combination therapy associating preferably a ceramide with a cytotoxic drug |
| US20110166319A1 (en) * | 2005-02-11 | 2011-07-07 | Immunogen, Inc. | Process for preparing purified drug conjugates |
| CA2597407C (en) * | 2005-02-11 | 2013-09-10 | Immunogen, Inc. | Process for preparing stable drug conjugates |
| US7714016B2 (en) | 2005-04-08 | 2010-05-11 | Medarex, Inc. | Cytotoxic compounds and conjugates with cleavable substrates |
| WO2007019232A2 (en) | 2005-08-03 | 2007-02-15 | Immunogen, Inc. | Immunoconjugate formulations |
| EP3539572A1 (en) | 2005-08-24 | 2019-09-18 | ImmunoGen, Inc. | Process for preparing maytansinoid antibody conjugates |
| BRPI0617546A2 (pt) * | 2005-09-26 | 2011-07-26 | Medarex Inc | conjugado de fÁrmaco-anticorpo, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula de tumor, mÉtodo para retardar ou interromper o crescimento de um tumor em um sujeito mamÍfero e composto |
| SI1940789T1 (sl) | 2005-10-26 | 2012-03-30 | Medarex Inc | Postopki in spojine za pripravo cc analogov |
| CA2627190A1 (en) | 2005-11-10 | 2007-05-24 | Medarex, Inc. | Duocarmycin derivatives as novel cytotoxic compounds and conjugates |
| EP1806365A1 (en) | 2006-01-05 | 2007-07-11 | Boehringer Ingelheim International GmbH | Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them |
| ES2673822T3 (es) | 2006-07-18 | 2018-06-25 | Sanofi | Anticuerpo antagonista contra EphA2 para el tratamiento de cáncer |
| EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| TWI412367B (zh) | 2006-12-28 | 2013-10-21 | 梅達雷克斯有限責任公司 | 化學鏈接劑與可裂解基質以及其之綴合物 |
| US9090693B2 (en) | 2007-01-25 | 2015-07-28 | Dana-Farber Cancer Institute | Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease |
| CA2678514A1 (en) | 2007-02-21 | 2008-08-28 | Medarex, Inc. | Chemical linkers with single amino acids and conjugates thereof |
| ES2542152T3 (es) | 2007-03-15 | 2015-07-31 | Ludwig Institute For Cancer Research Ltd. | Método de tratamiento que emplea anticuerpos de EGFR e inhibidores de Src y formulaciones relacionadas |
| PE20140196A1 (es) | 2007-08-09 | 2014-03-19 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
| CN108424454B (zh) | 2007-08-14 | 2022-05-31 | 路德维格癌症研究所有限公司 | 靶向egf受体的单克隆抗体175及其衍生物和用途 |
| AU2008304748C1 (en) | 2007-09-26 | 2014-06-12 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant region |
| US8742076B2 (en) * | 2008-02-01 | 2014-06-03 | Genentech, Inc. | Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods |
| FR2933702A1 (fr) * | 2008-07-08 | 2010-01-15 | Sanofi Aventis | Antagonistes specifiques du recepteur fgf-r4 |
| CN102159248B (zh) * | 2008-07-15 | 2013-09-11 | 健泰科生物技术公司 | 蒽环类衍生物缀合物、它们的制备方法以及它们作为抗肿瘤化合物的用途 |
| MY173526A (en) | 2009-03-25 | 2020-01-31 | Genentech Inc | Novel anti-?5?1 antibodies and uses thereof |
| BRPI1010620B8 (pt) | 2009-06-03 | 2021-05-25 | Immunogen Inc | métodos de conjugação |
| KR20120108967A (ko) | 2009-09-16 | 2012-10-05 | 제넨테크, 인크. | 코일드 코일 및/또는 테더 함유 단백질 복합체 및 그의 용도 |
| TW201116297A (en) | 2009-10-02 | 2011-05-16 | Sanofi Aventis | Antibodies that specifically bind to the EphA2 receptor |
| EP2486023A4 (en) | 2009-10-06 | 2014-05-07 | Immunogen Inc | EFFICIENT CONJUGATES AND HYDROPHILIC BINDER |
| PH12012500881A1 (en) | 2009-12-10 | 2017-07-26 | Hoffmann La Roche | Antibodies binding preferentially human csf1r extracellular domain 4 and their use |
| DK2536748T3 (da) | 2010-02-18 | 2014-10-13 | Genentech Inc | Neuregulin-antagonister og anvendelse deraf ved behandling af kræft |
| CA2789076C (en) | 2010-03-05 | 2017-11-21 | F. Hoffmann-La Roche Ag | Antibodies against human colony stimulating factor-1 receptor and uses thereof |
| CN102918061B (zh) | 2010-03-05 | 2016-06-08 | 霍夫曼-拉罗奇有限公司 | 针对人csf-1r的抗体及其用途 |
| AR080795A1 (es) | 2010-03-24 | 2012-05-09 | Genentech Inc | Anticuerpos anti-lrp6 (proteina relacionada con el receptor ldl tipo 6) |
| TW201138821A (en) | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
| BR112012027995A2 (pt) | 2010-06-18 | 2017-01-10 | Genentech Inc | anticorpo e ácido nucleíco isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, uso do anticorpo, método de tratamento de um indivíduo com câncer, de um indivíduo possuíndo um distúrbio imune, de inibição da angiogênese e para inibir a ativação constitutiva de axl |
| WO2011161119A1 (en) | 2010-06-22 | 2011-12-29 | F. Hoffmann-La Roche Ag | Antibodies against insulin-like growth factor i receptor and uses thereof |
| WO2011161189A1 (en) | 2010-06-24 | 2011-12-29 | F. Hoffmann-La Roche Ag | Anti-hepsin antibodies and methods of use |
| JP2013541501A (ja) | 2010-08-03 | 2013-11-14 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 慢性リンパ性白血病（ｃｌｌ）のバイオマーカー |
| HUE036077T2 (hu) | 2010-08-13 | 2018-06-28 | Roche Glycart Ag | Anti-FAP ellenanyagok és alkalmazásukra szolgáló eljárások |
| JP5841149B2 (ja) | 2010-08-13 | 2016-01-13 | ロシュ グリクアート アーゲー | 抗テネイシンｃａ２抗体及び使用の方法 |
| RU2013110844A (ru) | 2010-08-13 | 2014-09-20 | Дженентек, Инк. | АНТИТЕЛА ПРОТИВ IL-1β И IL-18, ИСПОЛЬЗУЕМЫЕ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ |
| KR20130103734A (ko) | 2010-08-31 | 2013-09-24 | 제넨테크, 인크. | 바이오마커 및 치료 방법 |
| MX346500B (es) | 2010-11-10 | 2017-03-22 | Genentech Inc * | Metodos y composiciones para inmunoterapia para enfermedad neural. |
| ES2533710T3 (es) | 2010-12-02 | 2015-04-14 | Nerviano Medical Sciences S.R.L. | Proceso para la preparación de derivados de morfolinil antraciclina |
| TWI732259B (zh) | 2010-12-16 | 2021-07-01 | 美商建南德克公司 | 關於th2抑制作用之診斷及治療 |
| PE20141114A1 (es) | 2010-12-20 | 2014-09-15 | Genentech Inc | Anticuerpos anti-mesotelina e inmunoconjugados |
| KR20130118925A (ko) | 2010-12-22 | 2013-10-30 | 제넨테크, 인크. | 항-pcsk9 항체 및 사용 방법 |
| JP5766296B2 (ja) | 2010-12-23 | 2015-08-19 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用 |
| RS58367B1 (sr) | 2011-03-29 | 2019-03-29 | Immunogen Inc | Priprema konjugata antitela i majtanzinoida jednostepenim postupkom |
| WO2012135517A2 (en) | 2011-03-29 | 2012-10-04 | Immunogen, Inc. | Preparation of maytansinoid antibody conjugates by a one-step process |
| SG10201602394QA (en) | 2011-03-29 | 2016-05-30 | Roche Glycart Ag | Antibody FC Variants |
| CA2828890A1 (en) | 2011-04-07 | 2012-10-11 | Genentech, Inc. | Anti-fgfr4 antibodies and methods of use |
| US20120282176A1 (en) | 2011-04-20 | 2012-11-08 | Roche Glycart Ag | Method and Constructs for the pH Dependent Passage of the Blood-brain-barrier |
| SI2710035T1 (sl) | 2011-05-16 | 2017-07-31 | F. Hoffmann-La Roche Ag | Agonisti FGFR1 in tehnike njihove uporabe |
| WO2012171020A1 (en) | 2011-06-10 | 2012-12-13 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| RU2013155695A (ru) | 2011-06-30 | 2015-08-10 | Дженентек, Инк. | Препараты антител против с-мет |
| US20140363438A1 (en) | 2011-08-17 | 2014-12-11 | Genentech, Inc. | Neuregulin antibodies and uses thereof |
| BR112014004168A2 (pt) | 2011-08-23 | 2017-12-12 | Roche Glycart Ag | anticorpo biespecífico, composição farmacêutica, uso do anticorpo biespecífico, célula hospedeira procariótica ou eucariótica, método de produção de anticorpo e invenção |
| WO2013026835A1 (en) | 2011-08-23 | 2013-02-28 | Roche Glycart Ag | Fc-free antibodies comprising two fab fragments and methods of use |
| JP2014533927A (ja) | 2011-09-15 | 2014-12-18 | ジェネンテック， インコーポレイテッド | 分化を促進する方法 |
| AU2012312515A1 (en) | 2011-09-19 | 2014-03-13 | Genentech, Inc. | Combination treatments comprising c-met antagonists and B-raf antagonists |
| KR101684750B1 (ko) | 2011-09-23 | 2016-12-08 | 로슈 글리카트 아게 | 이중특이적 항-egfr/항-igf-1r 항체 |
| US20130089562A1 (en) | 2011-10-05 | 2013-04-11 | Genenthech, Inc. | Methods of treating liver conditions using notch2 antagonists |
| CN103917556B (zh) | 2011-10-14 | 2018-02-06 | 霍夫曼-拉罗奇有限公司 | 抗HtrA1抗体及使用方法 |
| JP6134725B2 (ja) | 2011-10-14 | 2017-05-24 | ジェネンテック， インコーポレイテッド | Ｂａｃｅ１のペプチド阻害剤 |
| WO2013056148A2 (en) | 2011-10-15 | 2013-04-18 | Genentech, Inc. | Methods of using scd1 antagonists |
| PE20142312A1 (es) | 2011-10-28 | 2015-01-25 | Genentech Inc | Combinaciones terapeuticas y metodos para tratar el melanoma |
| EP2782932A1 (en) | 2011-11-21 | 2014-10-01 | F.Hoffmann-La Roche Ag | Purification of anti-c-met antibodies |
| BR112014012624A2 (pt) | 2011-12-15 | 2018-10-09 | F Hoffmann-La Roche Ag | anticorpos, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira, método para a produção de um anticorpo recombinante e uso do anticorpo |
| EP2804629A1 (en) | 2012-01-18 | 2014-11-26 | Genentech, Inc. | Anti-lrp5 antibodies and methods of use |
| US20130183294A1 (en) | 2012-01-18 | 2013-07-18 | Genentech, Inc. | Methods of using fgf19 modulators |
| WO2013119966A2 (en) | 2012-02-10 | 2013-08-15 | Genentech, Inc. | Single-chain antibodies and other heteromultimers |
| KR102148303B1 (ko) | 2012-02-11 | 2020-08-26 | 제넨테크, 인크. | R-스폰딘 전위 및 그의 사용 방법 |
| CA2860600C (en) | 2012-02-15 | 2022-07-26 | F. Hoffmann-La Roche Ag | Fc-receptor based affinity chromatography |
| AR090549A1 (es) | 2012-03-30 | 2014-11-19 | Genentech Inc | Anticuerpos anti-lgr5 e inmunoconjugados |
| WO2013160396A1 (en) | 2012-04-26 | 2013-10-31 | Boehringer Ingelheim International Gmbh | Combination of cd37 antibodies with bendamustine |
| AU2013256596A1 (en) | 2012-05-01 | 2014-10-09 | Genentech, Inc. | Anti-PMEL17 antibodies and immunoconjugates |
| WO2013170191A1 (en) | 2012-05-11 | 2013-11-14 | Genentech, Inc. | Methods of using antagonists of nad biosynthesis from nicotinamide |
| WO2013171287A1 (en) | 2012-05-16 | 2013-11-21 | Boehringer Ingelheim International Gmbh | Combination of cd37 antibodies with ice (ifosfamide, carboplatin, etoposide) |
| EP2849783A1 (en) | 2012-05-16 | 2015-03-25 | Boehringer Ingelheim International GmbH | Combination of cd37 antibodies with further agents |
| EP2855520B1 (en) | 2012-06-04 | 2018-09-26 | Novartis AG | Site-specific labeling methods and molecules produced thereby |
| EP2861624A1 (en) | 2012-06-15 | 2015-04-22 | F. Hoffmann-La Roche AG | Anti-pcsk9 antibodies, formulations, dosing, and methods of use |
| MX354862B (es) | 2012-06-27 | 2018-03-23 | Hoffmann La Roche | Método para la producción de entidades dirigidas altamente selectivas hechas a la medida y biespecíficas que contienen dos entidades de unión diferentes. |
| CA2871386A1 (en) | 2012-06-27 | 2014-01-03 | F. Hoffmann-La Roche Ag | Method for the selection and production of tailor-made, selective and multi-specific therapeutic molecules comprising at least two different targeting entities and uses thereof |
| WO2014001325A1 (en) | 2012-06-27 | 2014-01-03 | F. Hoffmann-La Roche Ag | Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof |
| ES2604012T3 (es) | 2012-07-04 | 2017-03-02 | F. Hoffmann-La Roche Ag | Conjugados de antígeno-anticuerpo unidos covalentemente |
| JP6247287B2 (ja) | 2012-07-04 | 2017-12-13 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 抗ビオチン抗体および使用方法 |
| EP3138578B1 (en) | 2012-07-04 | 2022-01-12 | F. Hoffmann-La Roche AG | Anti-theophylline antibodies and methods of use |
| EP2869851A1 (en) | 2012-07-09 | 2015-05-13 | Genentech, Inc. | Immunoconjugates comprising anti-cd22 antibodies |
| KR20150030698A (ko) | 2012-07-09 | 2015-03-20 | 제넨테크, 인크. | 항-cd79b 항체를 포함하는 면역접합체 |
| LT3495387T (lt) | 2012-07-13 | 2021-11-25 | Roche Glycart Ag | Bispecifiniai anti-vegf / anti-ang-2 antikūnai ir jų panaudojimas akių kraujagyslių ligoms gydyti |
| WO2014055877A1 (en) | 2012-10-04 | 2014-04-10 | Immunogen, Inc. | Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates |
| EP2904016B1 (en) | 2012-10-08 | 2018-11-14 | Roche Glycart AG | Fc-free antibodies comprising two fab-fragments and methods of use |
| MX2015005757A (es) | 2012-11-08 | 2015-11-18 | Hoffmann La Roche | Proteinas ligantes de antigeno her3 de union a la horquilla beta de her3. |
| SG10201700488QA (en) | 2012-11-13 | 2017-02-27 | Genentech Inc | Anti-hemagglutinin antibodies and methods of use |
| US10131682B2 (en) | 2012-11-24 | 2018-11-20 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules |
| CA2892863C (en) | 2012-12-10 | 2022-03-15 | Mersana Therapeutics, Inc. | Polymeric scaffold based on phf for targeted drug delivery |
| US10226535B2 (en) | 2012-12-10 | 2019-03-12 | Mersana Therapeutics, Inc. | Auristatin compounds and conjugates thereof |
| WO2014093640A1 (en) | 2012-12-12 | 2014-06-19 | Mersana Therapeutics,Inc. | Hydroxy-polmer-drug-protein conjugates |
| WO2014107739A1 (en) | 2013-01-07 | 2014-07-10 | Eleven Biotherapeutics, Inc. | Antibodies against pcsk9 |
| WO2014124258A2 (en) | 2013-02-08 | 2014-08-14 | Irm Llc | Specific sites for modifying antibodies to make immunoconjugates |
| KR102447350B1 (ko) | 2013-02-08 | 2022-09-23 | 노파르티스 아게 | 면역접합체의 제조를 위한 항체의 변형에 사용되는 특정 부위 |
| EP2958592A1 (en) | 2013-02-22 | 2015-12-30 | F. Hoffmann-La Roche AG | Methods of treating cancer and preventing drug resistance |
| RU2015140921A (ru) | 2013-02-26 | 2017-04-03 | Роше Гликарт Аг | Антитела к mcsp |
| KR20150123250A (ko) | 2013-03-06 | 2015-11-03 | 제넨테크, 인크. | 암 약물 내성의 치료 및 예방 방법 |
| US9498532B2 (en) | 2013-03-13 | 2016-11-22 | Novartis Ag | Antibody drug conjugates |
| US9562099B2 (en) | 2013-03-14 | 2017-02-07 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
| KR20150127216A (ko) | 2013-03-14 | 2015-11-16 | 제넨테크, 인크. | 암의 치료 및 암 약물 내성의 예방 방법 |
| AU2014244424A1 (en) | 2013-03-14 | 2015-08-27 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
| CN105143258B (zh) | 2013-03-15 | 2020-06-23 | Ac免疫有限公司 | 抗Tau抗体和使用方法 |
| SG10201706210WA (en) | 2013-03-15 | 2017-09-28 | Genentech Inc | Compositions and methods for diagnosis and treatment of hepatic cancers |
| NZ710929A (en) | 2013-03-15 | 2018-02-23 | Novartis Ag | Antibody drug conjugates |
| KR102389677B1 (ko) | 2013-03-15 | 2022-04-21 | 제넨테크, 인크. | Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법 |
| EP2970471A2 (en) | 2013-03-15 | 2016-01-20 | F. Hoffmann-La Roche AG | Anti-crth2 antibodies and their use |
| WO2014144850A1 (en) | 2013-03-15 | 2014-09-18 | Genentech, Inc. | Methods of treating cancer and preventing cancer drug resistance |
| AR095882A1 (es) | 2013-04-22 | 2015-11-18 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9 |
| RU2687043C2 (ru) | 2013-04-29 | 2019-05-06 | Ф. Хоффманн-Ля Рош Аг | МОДИФИЦИРОВАННЫЕ АСИММЕТРИЧНЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Fc-РЕЦЕПТОР, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| WO2014189973A2 (en) | 2013-05-20 | 2014-11-27 | Genentech, Inc. | Anti-transferrin receptor antibodies and methods of use |
| AR097584A1 (es) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
| WO2015042108A1 (en) | 2013-09-17 | 2015-03-26 | Genentech, Inc. | Methods of using anti-lgr5 antibodies |
| CA2927022C (en) | 2013-10-11 | 2018-08-21 | Asana Biosciences, Llc | Protein-polymer-drug conjugates |
| EA032231B1 (ru) | 2013-10-11 | 2019-04-30 | Мерсана Терапьютикс, Инк. | Конъюгаты белок-полимер-лекарственное средство |
| CN105744954B (zh) | 2013-10-18 | 2021-03-05 | 豪夫迈·罗氏有限公司 | 抗rspo2和/或抗rspo3抗体及其用途 |
| EA201691214A1 (ru) | 2013-12-13 | 2016-12-30 | Дженентек, Инк. | Антитела к cd33 и иммуноконъюгаты |
| JP6671292B2 (ja) | 2013-12-16 | 2020-03-25 | ジェネンテック， インコーポレイテッド | ペプチド模倣化合物及びその抗体−薬物コンジュゲート |
| TWI728373B (zh) | 2013-12-23 | 2021-05-21 | 美商建南德克公司 | 抗體及使用方法 |
| MX373856B (es) | 2014-01-03 | 2020-03-25 | Hoffmann La Roche | Conjugados helicoidales-anticuerpo anti-helicoidal unidos covalentemente y usos de los mismos. |
| CA2933384A1 (en) | 2014-01-03 | 2015-07-09 | F. Hoffmann-La Roche Ag | Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles |
| BR112016014945A2 (pt) | 2014-01-03 | 2018-01-23 | F. Hoffmann-La Roche Ag | conjugado, formulação farmacêutica e uso |
| PL3105253T3 (pl) | 2014-02-12 | 2018-12-31 | F. Hoffmann-La Roche Ag | Przeciwciała anty-Jagged1 i sposoby stosowania |
| JP2017507939A (ja) | 2014-02-21 | 2017-03-23 | ジェネンテック， インコーポレイテッド | 抗ｉｌ−１３／ｉｌ−１７二重特異性抗体及びその使用 |
| CA2938919C (en) | 2014-02-28 | 2020-12-29 | Hangzhou Dac Biotech Co., Ltd | Charged linkers and their uses for conjugation |
| CA2940451A1 (en) | 2014-03-12 | 2015-09-17 | Novartis Ag | Specific sites for modifying antibodies to make immunoconjugates |
| EP3116999B1 (en) | 2014-03-14 | 2021-09-15 | F. Hoffmann-La Roche AG | Methods and compositions for secretion of heterologous polypeptides |
| EP3119490B1 (en) | 2014-03-21 | 2021-09-08 | F. Hoffmann-La Roche AG | In vitro prediction of in vivo half-life of antibodies |
| EP3122900A1 (en) | 2014-03-24 | 2017-02-01 | F. Hoffmann-La Roche AG | Cancer treatment with c-met antagonists and correlation of the latter with hgf expression |
| RU2016142476A (ru) | 2014-03-31 | 2018-05-07 | Дженентек, Инк. | Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40 |
| EP3126394B1 (en) | 2014-03-31 | 2019-10-30 | F.Hoffmann-La Roche Ag | Anti-ox40 antibodies and methods of use |
| WO2015179658A2 (en) | 2014-05-22 | 2015-11-26 | Genentech, Inc. | Anti-gpc3 antibodies and immunoconjugates |
| KR20170005016A (ko) | 2014-05-23 | 2017-01-11 | 제넨테크, 인크. | MiT 바이오마커 및 그의 사용 방법 |
| CN107073121A (zh) | 2014-06-13 | 2017-08-18 | 基因泰克公司 | 治疗及预防癌症药物抗性的方法 |
| KR20170026362A (ko) | 2014-06-26 | 2017-03-08 | 에프. 호프만-라 로슈 아게 | 항-ｂｒｄｕ 항체 및 사용 방법 |
| CA2952315A1 (en) | 2014-07-11 | 2016-01-14 | Genentech, Inc. | Notch pathway inhibition |
| US10786578B2 (en) | 2014-08-05 | 2020-09-29 | Novartis Ag | CKIT antibody drug conjugates |
| KR20170040249A (ko) | 2014-08-12 | 2017-04-12 | 노파르티스 아게 | 항-cdh6 항체 약물 접합체 |
| WO2016033331A1 (en) | 2014-08-28 | 2016-03-03 | Bioatla, Llc | Conditionally active chimeric antigen receptors for modified t-cells |
| TWI805109B (zh) | 2014-08-28 | 2023-06-11 | 美商奇諾治療有限公司 | 對cd19具專一性之抗體及嵌合抗原受體 |
| KR20170066421A (ko) | 2014-09-12 | 2017-06-14 | 제넨테크, 인크. | 항-cll-1 항체 및 면역접합체 |
| MX2017003123A (es) | 2014-09-12 | 2017-05-12 | Genentech Inc | Anticuerpos y conjugados modificados geneticamente con cisteina. |
| WO2016040825A1 (en) | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Anthracycline disulfide intermediates, antibody-drug conjugates and methods |
| LT3191135T (lt) | 2014-09-12 | 2020-11-25 | Genentech, Inc. | Anti-her2 antikūnai ir imunokonjugatai |
| JP6943760B2 (ja) | 2014-09-12 | 2021-10-06 | ジェネンテック， インコーポレイテッド | 抗ｂ７−ｈ４抗体及び免疫複合体 |
| US9732148B2 (en) | 2014-10-16 | 2017-08-15 | Genentech, Inc. | Anti-α-synuclein antibodies and methods of use |
| CN107148283A (zh) | 2014-10-31 | 2017-09-08 | 豪夫迈·罗氏有限公司 | 抗il‑17a和il‑17f交叉反应性抗体变体、包含其的组合物及其制备和使用方法 |
| MX2017005751A (es) | 2014-11-03 | 2018-04-10 | Genentech Inc | Métodos y biomarcadores para predecir la eficacia y evaluación de un tratamiento con agonista de ox40. |
| EP3215850B1 (en) | 2014-11-03 | 2019-07-03 | F. Hoffmann-La Roche AG | Assays for detecting t cell immune subsets and methods of use thereof |
| RS59340B1 (sr) | 2014-11-06 | 2019-10-31 | Hoffmann La Roche | Varijante fc regiona sa modifikovanim vezivanjem za fcrn i metode upotrebe |
| WO2016073157A1 (en) | 2014-11-06 | 2016-05-12 | Genentech, Inc. | Anti-ang2 antibodies and methods of use thereof |
| TWI705976B (zh) | 2014-11-10 | 2020-10-01 | 美商建南德克公司 | 抗介白素-33抗體及其用途 |
| WO2016075670A1 (en) | 2014-11-14 | 2016-05-19 | Novartis Ag | Antibody drug conjugates |
| EP3221361B1 (en) | 2014-11-19 | 2021-04-21 | Genentech, Inc. | Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use |
| WO2016081639A1 (en) | 2014-11-19 | 2016-05-26 | Genentech, Inc. | Antibodies against bace1 and use thereof for neural disease immunotherapy |
| EP3221362B1 (en) | 2014-11-19 | 2019-07-24 | F.Hoffmann-La Roche Ag | Anti-transferrin receptor antibodies and methods of use |
| CN107001482B (zh) | 2014-12-03 | 2021-06-15 | 豪夫迈·罗氏有限公司 | 多特异性抗体 |
| MA40938A (fr) | 2014-12-05 | 2017-10-11 | Hoffmann La Roche | Anticorps anti-cd79b et méthodes d'utilisation desdits anticorps |
| RU2017120039A (ru) | 2014-12-10 | 2019-01-10 | Дженентек, Инк. | Антитела к рецепторам гематоэнцефалического барьера и способы их применения |
| CN107207607B (zh) | 2014-12-19 | 2021-05-04 | 中外制药株式会社 | 抗-c5抗体及使用方法 |
| KR101860280B1 (ko) | 2014-12-19 | 2018-05-21 | 추가이 세이야쿠 가부시키가이샤 | 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법 |
| JP6865688B2 (ja) | 2015-01-16 | 2021-04-28 | ジュノー セラピューティクス インコーポレイテッド | Ｒｏｒ１に特異的な抗体およびキメラ抗原受容体 |
| CN107428823B (zh) | 2015-01-22 | 2021-10-26 | 中外制药株式会社 | 两种以上抗-c5抗体的组合与使用方法 |
| CN114773470A (zh) | 2015-02-05 | 2022-07-22 | 中外制药株式会社 | 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用 |
| EP3286315B1 (en) | 2015-04-24 | 2021-05-26 | F. Hoffmann-La Roche AG | Methods of identifying bacteria comprising binding polypeptides |
| EP3778640A1 (en) | 2015-05-01 | 2021-02-17 | Genentech, Inc. | Masked anti-cd3 antibodies and methods of use |
| WO2016183104A1 (en) | 2015-05-11 | 2016-11-17 | Genentech, Inc. | Compositions and methods of treating lupus nephritis |
| RS61152B2 (sr) | 2015-05-12 | 2024-06-28 | Hoffmann La Roche | Terapeutski i dijagnostički postupci za lečenje raka |
| JP7144935B2 (ja) | 2015-05-29 | 2022-09-30 | ジェネンテック， インコーポレイテッド | 癌のための治療方法及び診断方法 |
| WO2016196343A1 (en) | 2015-05-29 | 2016-12-08 | Genentech, Inc. | Humanized anti-ebola virus glycoprotein antibodies and methods of use |
| KR20180011839A (ko) | 2015-06-08 | 2018-02-02 | 제넨테크, 인크. | 항-ox40 항체를 이용한 암의 치료 방법 |
| HK1251474A1 (zh) | 2015-06-08 | 2019-02-01 | 豪夫迈‧罗氏有限公司 | 使用抗ox40抗体和pd-1轴结合拮抗剂治疗癌症的方法 |
| EP3916018A1 (en) | 2015-06-16 | 2021-12-01 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
| TWI731861B (zh) | 2015-06-16 | 2021-07-01 | 美商建南德克公司 | FcRH5之人源化及親和力成熟抗體及使用方法 |
| EP3310378B1 (en) | 2015-06-16 | 2024-01-24 | F. Hoffmann-La Roche AG | Anti-cll-1 antibodies and methods of use |
| CN107787331B (zh) | 2015-06-17 | 2022-01-11 | 豪夫迈·罗氏有限公司 | 抗her2抗体和使用方法 |
| EP3310813A1 (en) | 2015-06-17 | 2018-04-25 | Novartis AG | Antibody drug conjugates |
| WO2016207091A1 (en) | 2015-06-24 | 2016-12-29 | F. Hoffmann-La Roche Ag | Trispecific antibodies specific for her2 and a blood brain barrier receptor and methods of use |
| MX391086B (es) | 2015-06-24 | 2025-03-21 | Hoffmann La Roche | Anticuerpos anti-receptor de transferrina con afinidad diseñada. |
| KR20180021864A (ko) | 2015-06-29 | 2018-03-05 | 제넨테크, 인크. | 장기 이식에서 사용하기 위한 유형 ii 항-cd20 항체 |
| FI3319936T3 (fi) | 2015-07-12 | 2026-03-12 | Hangzhou Dac Biotech Co Ltd | Silloituslinkkereitä soluun sitoutuvien molekyylien konjugoimiseksi |
| US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
| PE20180802A1 (es) | 2015-08-05 | 2018-05-09 | Janssen Biotech Inc | Anticuerpos anti-cd154 y metodos de uso de estos |
| EP3331569A1 (en) | 2015-08-07 | 2018-06-13 | Gamamabs Pharma | Antibodies, antibody drug conjugates and methods of use |
| CN105384825B (zh) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| RU2763916C2 (ru) | 2015-09-23 | 2022-01-11 | Дженентек, Инк. | Оптимизированные варианты анти-vegf антител |
| AU2016326738B2 (en) | 2015-09-24 | 2023-08-31 | Abvitro Llc | HIV antibody compositions and methods of use |
| CA2994858C (en) | 2015-09-25 | 2024-01-23 | Genentech, Inc. | Anti-tigit antibodies and methods of use |
| CR20180177A (es) | 2015-09-30 | 2018-06-22 | Janssen Biotech Inc | Anticuerpos agonistas que se unen específicamente a cd40 humana y método de uso |
| AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
| NZ739090A (en) | 2015-10-02 | 2025-06-27 | Hoffmann La Roche | Bispecific antibodies specific for pd1 and tim3 |
| CR20180151A (es) | 2015-10-02 | 2018-05-25 | Hoffmann La Roche | Antcuierpos anti-pd1 y métodos de uso |
| NZ741067A (en) | 2015-10-02 | 2023-07-28 | Hoffmann La Roche | Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use |
| EP3362100B1 (en) | 2015-10-16 | 2022-06-22 | Genentech, Inc. | Hindered disulfide drug conjugates |
| EP3184547A1 (en) | 2015-10-29 | 2017-06-28 | F. Hoffmann-La Roche AG | Anti-tpbg antibodies and methods of use |
| ES2904553T3 (es) | 2015-10-30 | 2022-04-05 | Hoffmann La Roche | Fragmentos de anticuerpo modificados con bisagra y procedimientos de preparación |
| EP3370768B9 (en) | 2015-11-03 | 2022-03-16 | Janssen Biotech, Inc. | Antibodies specifically binding pd-1 and their uses |
| EP3371217B1 (en) | 2015-11-08 | 2025-06-11 | F. Hoffmann-La Roche AG | Methods of screening for multispecific antibodies |
| EP3178848A1 (en) | 2015-12-09 | 2017-06-14 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies |
| EP4026848A1 (en) | 2015-12-09 | 2022-07-13 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody for reducing the cytokine release syndrome |
| WO2017100402A1 (en) * | 2015-12-11 | 2017-06-15 | Archer Daniels Midland Company | One-pot synthesis of anhydropentitol esters from pentitols, catalyzed by water-tolerant lewis acids |
| IL259256B2 (en) | 2015-12-18 | 2023-02-01 | Chugai Pharmaceutical Co Ltd | Anti-c5 antibodies and methods of use |
| TWI605057B (zh) | 2015-12-18 | 2017-11-11 | 中外製藥股份有限公司 | 抗肌抑素抗體、含變異ｆｃ區之多肽及使用方法 |
| JP6821693B2 (ja) | 2016-02-29 | 2021-01-27 | ジェネンテック， インコーポレイテッド | がんのための治療方法及び診断方法 |
| JP2019513371A (ja) | 2016-04-01 | 2019-05-30 | アビディティー バイオサイエンシーズ エルエルシー | 核酸ポリペプチド組成物とその使用 |
| EP3443004A1 (en) | 2016-04-14 | 2019-02-20 | H. Hoffnabb-La Roche Ag | Anti-rspo3 antibodies and methods of use |
| CN109154613A (zh) | 2016-04-15 | 2019-01-04 | 豪夫迈·罗氏有限公司 | 用于监测和治疗癌症的方法 |
| AU2017248766A1 (en) | 2016-04-15 | 2018-11-01 | Genentech, Inc. | Methods for monitoring and treating cancer |
| PL3443012T3 (pl) | 2016-04-15 | 2026-04-20 | Bioatla, Inc. | Przeciwciała anty-axl, fragmenty przeciwciał i ich immunokoniugaty oraz ich zastosowania |
| AU2017259869A1 (en) | 2016-05-02 | 2018-09-27 | F. Hoffmann-La Roche Ag | The contorsbody - a single chain target binder |
| WO2017194441A1 (en) | 2016-05-11 | 2017-11-16 | F. Hoffmann-La Roche Ag | Modified anti-tenascin antibodies and methods of use |
| TW201808336A (zh) | 2016-05-11 | 2018-03-16 | 賽諾菲公司 | 用抗ｍｕｃ１類美登素免疫綴合物抗體治療腫瘤的治療方案 |
| CN116751298A (zh) | 2016-05-13 | 2023-09-15 | 生物蛋白有限公司 | 抗ror2抗体、抗体片段和它们的免疫缀合物以及其用途 |
| EP3465221B1 (en) | 2016-05-27 | 2020-07-22 | H. Hoffnabb-La Roche Ag | Bioanalytical method for the characterization of site-specific antibody-drug conjugates |
| TW201902512A (zh) | 2016-06-02 | 2019-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療方法 |
| EP3252078A1 (en) | 2016-06-02 | 2017-12-06 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
| KR102306744B1 (ko) | 2016-06-17 | 2021-09-28 | 추가이 세이야쿠 가부시키가이샤 | 항-마이오스타틴 항체 및 사용 방법 |
| CN109310765A (zh) * | 2016-06-20 | 2019-02-05 | 领先基因生物技术股份有限公司 | 抗体-药物偶联物 |
| US20240018268A1 (en) | 2016-07-29 | 2024-01-18 | Juno Therapeutics, Inc. | Anti-idiotypic antibodies against anti-cd19 antibodies |
| TWI693940B (zh) | 2016-08-05 | 2020-05-21 | 日商中外製藥股份有限公司 | Ｉｌ-８相關疾病之治療用或預防用組成物 |
| US11046776B2 (en) | 2016-08-05 | 2021-06-29 | Genentech, Inc. | Multivalent and multiepitopic antibodies having agonistic activity and methods of use |
| EP4282877A3 (en) | 2016-08-10 | 2024-02-21 | Legend Biotech Ireland Limited | Chimeric antigen receptors targeting bcma and methods of use thereof |
| CN109790220A (zh) | 2016-08-25 | 2019-05-21 | 豪夫迈·罗氏有限公司 | 与巨噬细胞激活剂组合的抗csf-1r抗体的间歇给药 |
| SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
| CN116731197A (zh) | 2016-09-19 | 2023-09-12 | 豪夫迈·罗氏有限公司 | 基于补体因子的亲和层析 |
| AU2017339517B2 (en) | 2016-10-06 | 2024-03-14 | Foundation Medicine, Inc. | Therapeutic and diagnostic methods for cancer |
| EP3532091A2 (en) | 2016-10-29 | 2019-09-04 | H. Hoffnabb-La Roche Ag | Anti-mic antibidies and methods of use |
| CA3042442C (en) | 2016-11-14 | 2024-01-02 | Hangzhou Dac Biotech Co., Ltd | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses of such conjugates with the linkers |
| WO2018093821A1 (en) | 2016-11-15 | 2018-05-24 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
| TW201829463A (zh) | 2016-11-18 | 2018-08-16 | 瑞士商赫孚孟拉羅股份公司 | 抗hla-g抗體及其用途 |
| JP7313684B2 (ja) | 2016-11-21 | 2023-07-25 | キュレアブ ゲーエムベーハー | 抗ｇｐ７３抗体及びイムノコンジュゲート |
| US11135307B2 (en) | 2016-11-23 | 2021-10-05 | Mersana Therapeutics, Inc. | Peptide-containing linkers for antibody-drug conjugates |
| CN110072553B (zh) | 2016-12-22 | 2023-09-15 | 豪夫迈·罗氏有限公司 | 在抗pd-l1/pd1治疗失败之后抗csf-1r抗体与抗pd-l1抗体组合对肿瘤的治疗 |
| MX2019008199A (es) | 2017-01-06 | 2019-11-25 | Avidity Biosciences Llc | Composiciones de acido nucleico polipeptido y metodos de induccion de la omision de exon. |
| JOP20190187A1 (ar) | 2017-02-03 | 2019-08-01 | Novartis Ag | مترافقات عقار جسم مضاد لـ ccr7 |
| PE20191548A1 (es) | 2017-02-10 | 2019-10-24 | Genentech Inc | Anticuerpos contra triptasa, composiciones de estos y usos de estos |
| CN110546277B (zh) | 2017-03-01 | 2024-06-11 | 豪夫迈·罗氏有限公司 | 用于癌症的诊断和治疗方法 |
| WO2018185618A1 (en) | 2017-04-03 | 2018-10-11 | Novartis Ag | Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment |
| EP3615572A1 (en) | 2017-04-27 | 2020-03-04 | Tesaro Inc. | Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof |
| EP3615068A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| JP7320458B2 (ja) | 2017-06-22 | 2023-08-03 | メルサナ セラピューティクス インコーポレイテッド | 薬物担持ポリマースキャフォールドおよびタンパク質－ポリマー－薬物コンジュゲートを製造する方法 |
| KR102922386B1 (ko) | 2017-07-21 | 2026-02-04 | 제넨테크, 인크. | 암에 대한 치료 및 진단 방법 |
| US11530413B2 (en) | 2017-07-21 | 2022-12-20 | Novartis Ag | Compositions and methods to treat cancer |
| GB201711809D0 (en) | 2017-07-21 | 2017-09-06 | Governors Of The Univ Of Alberta | Antisense oligonucleotide |
| WO2019078357A1 (ja) | 2017-10-20 | 2019-04-25 | 中外製薬株式会社 | 細胞への分子の取り込みを測定する方法 |
| BR112020007736A2 (pt) | 2017-10-30 | 2020-10-20 | F. Hoffmann-La Roche Ag | composição e método de tratamento |
| JP2021500930A (ja) | 2017-11-01 | 2021-01-14 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｃｏｍｐボディ−多価標的結合物質 |
| PL3704146T3 (pl) | 2017-11-01 | 2022-03-07 | F. Hoffmann-La Roche Ag | Przeciwciało Contorsbody trifab |
| AU2018358067A1 (en) | 2017-11-01 | 2020-05-07 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for B-cell maturation antigen |
| ES2984919T3 (es) | 2017-11-06 | 2024-10-31 | Hoffmann La Roche | Procedimientos diagnósticos y terapéuticos para el cáncer |
| EP3710589A4 (en) | 2017-11-14 | 2021-11-10 | Chugai Seiyaku Kabushiki Kaisha | ANTI-C1S ANTIBODIES AND METHOD OF USING |
| JP7506601B2 (ja) | 2017-12-06 | 2024-06-26 | アビディティー バイオサイエンシーズ，インク． | 筋萎縮症と筋緊張性ジストロフィーを処置するための組成物および方法 |
| US11667713B2 (en) | 2017-12-28 | 2023-06-06 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
| EP3737692A4 (en) | 2018-01-09 | 2021-09-29 | Elstar Therapeutics, Inc. | CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES |
| EP3740505A1 (en) | 2018-01-16 | 2020-11-25 | Lakepharma Inc. | Bispecific antibody that binds cd3 and another target |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| JP7475275B2 (ja) | 2018-02-08 | 2024-04-26 | ジェネンテック， インコーポレイテッド | 二重特異性抗原結合分子及びその使用方法 |
| CN111836831A (zh) | 2018-02-26 | 2020-10-27 | 豪夫迈·罗氏有限公司 | 用于抗tigit拮抗剂抗体和抗pd-l1拮抗剂抗体治疗的给药 |
| US20200040103A1 (en) | 2018-03-14 | 2020-02-06 | Genentech, Inc. | Anti-klk5 antibodies and methods of use |
| US12152073B2 (en) | 2018-03-14 | 2024-11-26 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| CA3093729A1 (en) | 2018-03-15 | 2019-09-19 | Chugai Seiyaku Kabushiki Kaisha | Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use |
| TW202011029A (zh) | 2018-04-04 | 2020-03-16 | 美商建南德克公司 | 偵測及定量fgf21之方法 |
| AR114789A1 (es) | 2018-04-18 | 2020-10-14 | Hoffmann La Roche | Anticuerpos anti-hla-g y uso de los mismos |
| AU2019271148B9 (en) | 2018-05-14 | 2025-05-29 | Werewolf Therapeutics, Inc. | Activatable interleukin-2 polypeptides and methods of use thereof |
| CA3100005A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| SG11202011633SA (en) | 2018-05-24 | 2020-12-30 | Janssen Biotech Inc | Psma binding agents and uses thereof |
| EP3818083A2 (en) | 2018-07-03 | 2021-05-12 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| EP3835321A4 (en) | 2018-08-10 | 2022-11-02 | Chugai Seiyaku Kabushiki Kaisha | ANTI-CD137 ANTIGEN-BINDING MOLECULE AND USE THEREOF |
| US12097219B2 (en) | 2018-09-10 | 2024-09-24 | Legend Biotech Ireland Limited | Single-domain antibodies against CLL1 and constructs thereof |
| JP2022501332A (ja) | 2018-09-19 | 2022-01-06 | ジェネンテック， インコーポレイテッド | 膀胱がんの治療方法および診断方法 |
| CN120463822A (zh) | 2018-09-27 | 2025-08-12 | 西里欧发展公司 | 掩蔽型细胞因子多肽 |
| MX2021004348A (es) | 2018-10-18 | 2021-05-28 | Genentech Inc | Procedimientos de diagnóstico y terapéuticos para el cáncer de riñón sarcomatoide. |
| EP3873519A1 (en) | 2018-10-29 | 2021-09-08 | F. Hoffmann-La Roche AG | Antibody formulation |
| AU2019369340A1 (en) | 2018-10-29 | 2021-05-20 | Mersana Therapeutics, Inc. | Cysteine engineered antibody-drug conjugates with peptide-containing linkers |
| EP3873532A1 (en) | 2018-10-31 | 2021-09-08 | Novartis AG | Dc-sign antibody drug conjugates |
| AR117453A1 (es) | 2018-12-20 | 2021-08-04 | Genentech Inc | Fc de anticuerpos modificados y métodos para utilizarlas |
| IL312067B2 (en) | 2018-12-21 | 2025-08-01 | Avidity Biosciences Inc | Anti-transferrin receptor antibodies and uses thereof |
| JP7607564B2 (ja) | 2018-12-21 | 2024-12-27 | ノバルティス アーゲー | Ｐｍｅｌ１７に対する抗体及びその結合体 |
| BR112021012536A2 (pt) | 2018-12-26 | 2021-09-14 | City Of Hope | Proteínas de ligação anti-ctla4 mascaradas ativáveis |
| BR112021014276A2 (pt) | 2019-01-22 | 2021-09-28 | Genentech, Inc. | Anticorpos iga isolados, moléculas de fusão igg-iga isoladas, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo, para tratar um indivíduo, para aumentar a expressão de dímeros, trímeros ou tetrâmeros, para aumentar a produção de polímeros, para aumentar a produção de dímeros, para aumentar a produção de um polímero, para diminuir a produção de polímeros, para aumentar a expressão transitória de um anticorpo, para expressar dímeros de moléculas de fusão, para expressar dímeros, trímeros ou tetrâmeros, para purificar um anticorpo, para purificar um estado oligomérico de um anticorpo, composição farmacêutica e uso do anticorpo |
| WO2020153467A1 (ja) | 2019-01-24 | 2020-07-30 | 中外製薬株式会社 | 新規がん抗原及びそれらの抗原に対する抗体 |
| CA3123303A1 (en) | 2019-01-29 | 2020-08-06 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1) |
| AU2020224681A1 (en) | 2019-02-21 | 2021-09-16 | Marengo Therapeutics, Inc. | Antibody molecules that bind to NKp30 and uses thereof |
| JP7710373B2 (ja) | 2019-02-21 | 2025-07-18 | マレンゴ・セラピューティクス，インコーポレーテッド | Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用 |
| KR20210133237A (ko) | 2019-02-27 | 2021-11-05 | 제넨테크, 인크. | 항-tigit 및 항-cd20 또는 항-cd38 항체로 치료를 위한 투약 |
| TW202100556A (zh) | 2019-03-14 | 2021-01-01 | 美商建南德克公司 | 使用her2 t細胞依賴性雙特異性抗體之治療 |
| CN120131907A (zh) | 2019-03-19 | 2025-06-13 | 瓦尔希伯伦私人肿瘤研究基金会 | 采用Omomyc和结合PD-1或CTLA-4的抗体治疗癌症的联合疗法 |
| BR112021020532A2 (pt) | 2019-04-19 | 2022-03-15 | Janssen Biotech Inc | Métodos para tratamento de câncer de próstata com um anticorpo anti-psma/cd3 |
| BR112021020867A2 (pt) | 2019-04-19 | 2022-01-04 | Genentech Inc | Anticorpos, ácido nucleico, vetor, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, usos do anticorpo, método de tratamento de um indivíduo com câncer e método para reduzir a depuração |
| US12497615B2 (en) | 2019-04-25 | 2025-12-16 | Avidity Biosciences, Inc. | Nucleic acid compositions and methods of multi-exon skipping |
| KR20220023988A (ko) | 2019-05-14 | 2022-03-03 | 웨어울프 세라퓨틱스, 인크. | 분리 모이어티 및 이의 사용 방법 |
| MX2021013441A (es) | 2019-05-15 | 2021-12-10 | Chugai Pharmaceutical Co Ltd | Molecula de union a antigenos, composicion farmaceutica y metodo. |
| CR20220049A (es) | 2019-07-10 | 2022-03-02 | Chugai Pharmaceutical Co Ltd | Moléculas de unión a claudina-6 y usos de las mismas |
| EP4048693A1 (en) | 2019-09-27 | 2022-08-31 | F. Hoffmann-La Roche AG | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
| AU2020378330A1 (en) | 2019-11-06 | 2022-05-12 | F. Hoffmann-La Roche Ag | Diagnostic and therapeutic methods for treatment of hematologic cancers |
| BR112022009110A2 (pt) | 2019-11-14 | 2022-07-26 | Werewolf Therapeutics Inc | Polipeptídeos de citocina ativáveis e métodos de uso destes |
| KR20220122656A (ko) | 2019-12-06 | 2022-09-02 | 주노 쎄러퓨티크스 인코퍼레이티드 | Ｇｐｒｃ5ｄ-표적화 결합 도메인에 대한 항-이디오타입 항체 및 관련 조성물 및 방법 |
| CN115916817A (zh) | 2019-12-06 | 2023-04-04 | 朱诺治疗学股份有限公司 | 针对bcma靶向结合结构域的抗独特型抗体及相关组合物和方法 |
| WO2021119505A1 (en) | 2019-12-13 | 2021-06-17 | Genentech, Inc. | Anti-ly6g6d antibodies and methods of use |
| MY202559A (en) | 2019-12-27 | 2024-05-08 | Chugai Pharmaceutical Co Ltd | Anti-ctla-4 antibody and use thereof |
| CN116234829A (zh) | 2020-01-03 | 2023-06-06 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
| IL294321B1 (en) | 2020-01-09 | 2026-04-01 | Mersana Therapeutics Inc | Antibody-drug conjugates are attached at a specific site with linkers that include peptides. |
| CN110818795B (zh) | 2020-01-10 | 2020-04-24 | 上海复宏汉霖生物技术股份有限公司 | 抗tigit抗体和使用方法 |
| WO2021194481A1 (en) | 2020-03-24 | 2021-09-30 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
| WO2022050954A1 (en) | 2020-09-04 | 2022-03-10 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
| TWI895351B (zh) | 2020-02-12 | 2025-09-01 | 日商中外製藥股份有限公司 | 用於癌症之治療的抗cd137抗原結合分子 |
| AU2021236306A1 (en) | 2020-03-13 | 2022-09-15 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
| US11555190B2 (en) | 2020-03-19 | 2023-01-17 | Avidity Biosciences, Inc. | Compositions and methods of treating Facioscapulohumeral muscular dystrophy |
| TWI867190B (zh) | 2020-03-19 | 2024-12-21 | 美商建南德克公司 | 同功型選擇性抗-TGF-β抗體及其使用方法 |
| AU2021241682B2 (en) | 2020-03-27 | 2026-02-12 | Avidity Biosciences, Inc. | Compositions and methods of treating muscle dystrophy |
| EP4127724A1 (en) | 2020-04-03 | 2023-02-08 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
| EP4143345A1 (en) | 2020-04-28 | 2023-03-08 | Genentech, Inc. | Methods and compositions for non-small cell lung cancer immunotherapy |
| US20230181756A1 (en) | 2020-04-30 | 2023-06-15 | Novartis Ag | Ccr7 antibody drug conjugates for treating cancer |
| WO2021252977A1 (en) | 2020-06-12 | 2021-12-16 | Genentech, Inc. | Methods and compositions for cancer immunotherapy |
| CN115916348A (zh) | 2020-06-18 | 2023-04-04 | 基因泰克公司 | 使用抗tigit抗体和pd-1轴结合拮抗剂的治疗 |
| EP4178624A2 (en) | 2020-07-07 | 2023-05-17 | Bionecure Therapeutics, Inc. | Maytansinoids as adc payloads and their use for the treatment of cancer |
| CA3188000A1 (en) | 2020-07-13 | 2022-01-20 | Genentech, Inc. | Cell-based methods for predicting polypeptide immunogenicity |
| JP7846667B2 (ja) | 2020-07-16 | 2026-04-15 | レジェンド バイオテック アイルランド リミテッド | Ｃｄ２０結合分子及びその使用 |
| JPWO2022025184A1 (https=) | 2020-07-29 | 2022-02-03 | ||
| WO2022029660A1 (en) | 2020-08-05 | 2022-02-10 | Juno Therapeutics, Inc. | Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods |
| CR20230119A (es) | 2020-08-07 | 2023-05-16 | Genentech Inc | Proteínas de fusión del ligando para flt3 y métodos de uso |
| CN115836122A (zh) | 2020-08-07 | 2023-03-21 | 基因泰克公司 | 用于预测多肽免疫原性的基于t细胞的方法 |
| KR20230082632A (ko) | 2020-10-05 | 2023-06-08 | 제넨테크, 인크. | 항-fcrh5/항-cd3 이중특이성 항체를 사용한 치료를 위한 투약 |
| CA3196539A1 (en) | 2020-11-04 | 2022-05-12 | Chi-Chung Li | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
| KR20230100732A (ko) | 2020-11-04 | 2023-07-05 | 제넨테크, 인크. | 항-cd20/항-cd3 이중특이성 항체의 피하 투여 |
| AU2021374594B2 (en) | 2020-11-04 | 2026-03-05 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates |
| EP4000635A1 (en) * | 2020-11-16 | 2022-05-25 | Frank J. Hernandez | Therapeutic-oligonucleotides activated by nucleases |
| CA3200858A1 (en) | 2020-11-24 | 2022-06-02 | Novartis Ag | Anti-cd48 antibodies, antibody drug conjugates, and uses thereof |
| WO2022115865A2 (en) | 2020-11-25 | 2022-06-02 | Xilio Development, Inc. | Tumor-specific cleavable linkers |
| WO2022116877A1 (en) | 2020-12-02 | 2022-06-09 | Shanghai Henlius Biotech, Inc. | ANTI-GARP/TGFβ ANTIBODIES AND METHODS OF USE |
| JP7326584B2 (ja) | 2020-12-17 | 2023-08-15 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 抗ｈｌａ－ｇ抗体及びその使用 |
| US20240059789A1 (en) | 2021-01-28 | 2024-02-22 | Janssen Biotech, Inc. | Psma binding proteins and uses thereof |
| WO2022187270A1 (en) | 2021-03-01 | 2022-09-09 | Xilio Development, Inc. | Combination of ctla4 and pd1/pdl1 antibodies for treating cancer |
| EP4301781A1 (en) | 2021-03-01 | 2024-01-10 | Xilio Development, Inc. | Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer |
| AR125344A1 (es) | 2021-04-15 | 2023-07-05 | Chugai Pharmaceutical Co Ltd | Anticuerpo anti-c1s |
| CA3235132A1 (en) | 2021-04-16 | 2022-10-20 | Novartis Ag | Antibody drug conjugates and methods for making thereof |
| CA3213632A1 (en) | 2021-04-30 | 2022-11-03 | F. Hoffmann-La Roche Ag | Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate |
| MX2023012699A (es) | 2021-04-30 | 2023-11-21 | Hoffmann La Roche | Dosificacion para el tratamiento con anticuerpo biespecifico anti-cd20/anti-cd3. |
| WO2022244838A1 (ja) | 2021-05-19 | 2022-11-24 | 中外製薬株式会社 | 分子のｉｎ ｖｉｖｏ薬物動態を予測する方法 |
| US20240270853A1 (en) | 2021-06-04 | 2024-08-15 | Chugai Seiyaku Kabushiki Kaisha | Anti-ddr2 antibodies and uses thereof |
| AU2022299846B2 (en) | 2021-06-25 | 2024-08-15 | Chugai Seiyaku Kabushiki Kaisha | Anti–ctla-4 antibody |
| TWI864408B (zh) | 2021-06-25 | 2024-12-01 | 日商中外製藥股份有限公司 | 抗ctla-4抗體的用途 |
| MX2024002476A (es) | 2021-08-27 | 2024-05-20 | Janssen Biotech Inc | Anticuerpos anti-psma y usos de estos. |
| MX2024003266A (es) | 2021-09-16 | 2024-04-03 | Avidity Biosciences Inc | Composiciones y metodos de tratamiento de la distrofia muscular facioescapulohumeral. |
| TW202321308A (zh) | 2021-09-30 | 2023-06-01 | 美商建南德克公司 | 使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法 |
| TW202333781A (zh) | 2021-10-08 | 2023-09-01 | 日商中外製藥股份有限公司 | 抗ｈｌａ－ｄｑ２﹒５抗體製劑 |
| CN117980327A (zh) | 2021-11-03 | 2024-05-03 | 杭州多禧生物科技有限公司 | 抗体的特异性偶联 |
| KR20240102971A (ko) | 2021-11-16 | 2024-07-03 | 제넨테크, 인크. | 모수네투주맙을 이용하여 전신 홍반성 루푸스(sle)를 치료하기 위한 방법과 조성물 |
| CN118488965A (zh) | 2021-12-17 | 2024-08-13 | 上海复宏汉霖生物技术股份有限公司 | 抗ox40抗体、多特异性抗体及其使用方法 |
| JP2025501522A (ja) | 2021-12-17 | 2025-01-22 | シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド | 抗ｏｘ４０抗体及び使用方法 |
| UY40097A (es) | 2022-01-07 | 2023-07-14 | Johnson & Johnson Entpr Innovation Inc | Materiales y métodos de proteínas de unión a il-1b |
| AU2022441090A1 (en) | 2022-02-17 | 2024-08-22 | Novelty Nobility Inc. | Antibody-drug conjugate. |
| WO2023180353A1 (en) | 2022-03-23 | 2023-09-28 | F. Hoffmann-La Roche Ag | Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy |
| JP2025514610A (ja) | 2022-03-25 | 2025-05-09 | シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド | 抗ｍｓｌｎ抗体及び使用方法 |
| IL315770A (en) | 2022-04-01 | 2024-11-01 | Genentech Inc | Dosage for treatment with bispecific anti-FCRH5/anti-CD3 antibodies |
| US12071621B2 (en) | 2022-04-05 | 2024-08-27 | Avidity Biosciences, Inc. | Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping |
| CN119013300A (zh) | 2022-04-13 | 2024-11-22 | 豪夫迈·罗氏有限公司 | 抗cd20/抗cd3双特异性抗体的药物组合物和使用方法 |
| TWI882313B (zh) | 2022-04-13 | 2025-05-01 | 美商建南德克公司 | 治療性蛋白質之醫藥組成物及使用方法 |
| WO2023215293A1 (en) | 2022-05-02 | 2023-11-09 | Athanor Biosciences, Inc. | Cancer eradicating – bio-nanoparticles (ce-bnp) |
| CN119317641A (zh) | 2022-05-11 | 2025-01-14 | 基因泰克公司 | 针对用抗fcrh5/抗cd3双特异性抗体进行治疗的给药 |
| EP4537107A2 (en) | 2022-06-07 | 2025-04-16 | Genentech, Inc. | Method for determining the efficacy of a lung cancer treatment comprising an anti-pd-l1 antagonist and an anti-tigit antagonist antibody |
| JP2025523020A (ja) | 2022-07-13 | 2025-07-17 | ジェネンテック， インコーポレイテッド | 抗ＦｃＲＨ５／抗ＣＤ３二重特異性抗体による処置のための投与 |
| JP2025524728A (ja) | 2022-07-15 | 2025-07-30 | フィアン セラピューティクス エルティーディー | 抗体－薬物複合体 |
| CA3261510A1 (en) | 2022-07-19 | 2024-01-25 | F. Hoffmann-La Roche Ag | DOSAGE FOR TREATMENT WITH BISOPECIFIC ANTI-FCRH5/ANTI-CD3 ANTIBODIES |
| CA3261989A1 (en) | 2022-07-22 | 2024-01-25 | Genentech, Inc. | ANTI-STEAP1 ANTIGEN-BINDING MOLECULES AND THEIR USES |
| JP2025531738A (ja) | 2022-09-01 | 2025-09-25 | ジェネンテック， インコーポレイテッド | 膀胱がんの治療方法及び診断方法 |
| AU2023370106A1 (en) | 2022-10-25 | 2025-05-08 | Fundació Privada Institut D'investigació Oncològica De Vall Hebron | Combination therapy for the treatment of cancer |
| WO2024091991A1 (en) | 2022-10-25 | 2024-05-02 | Genentech, Inc. | Therapeutic and diagnostic methods for multiple myeloma |
| WO2024102948A1 (en) | 2022-11-11 | 2024-05-16 | Celgene Corporation | Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods |
| CN120712102A (zh) | 2022-12-13 | 2025-09-26 | 朱诺治疗学股份有限公司 | 对baff-r和cd19具特异性的嵌合抗原受体及其方法和用途 |
| WO2024233341A1 (en) | 2023-05-05 | 2024-11-14 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
| TW202513088A (zh) | 2023-06-07 | 2025-04-01 | 瓦爾希伯倫私人腫瘤研究基金會 | 用於治療癌症的與ｍｅｋ抑制劑的組合療法 |
| KR20260020418A (ko) | 2023-06-07 | 2026-02-11 | 펀다시오 프리바다 인스티튜트 드인베스티가시오 온콜로지카 데 발 헤브론 | Braf 저해제를 이용한 암 치료용 조합 요법 |
| EP4473974A1 (en) | 2023-06-07 | 2024-12-11 | Peptomyc, S.L. | Omomyc and kras inhibitors combination therapy for the treatment of cancer |
| WO2025106474A1 (en) | 2023-11-14 | 2025-05-22 | Genentech, Inc. | Therapeutic and diagnostic methods for treating cancer with anti-fcrh5/anti-cd3 bispecific antibodies |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| WO2026030464A1 (en) | 2024-07-30 | 2026-02-05 | Genentech, Inc. | Dosage regimen for reducing cytokine release syndrome (crs) with anti-fcrh5/anti-cd3 bispecific antibodies in multiple myeloma therapy |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4672057A (en) * | 1985-03-22 | 1987-06-09 | Farmitalia Carlo Erba S.P.A. | Morpholino derivatives of daunorubicin and doxorubicin |
| EP0434960A1 (en) * | 1989-12-19 | 1991-07-03 | PHARMACIA S.p.A. | Chiral 1,5-diiodo-2-methoxy or benzyloxy intermediates |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4464529A (en) * | 1982-07-20 | 1984-08-07 | Sri International | Analogues of morpholinyl daunorubicin and morpholinyl doxorubicin |
| US5304687A (en) | 1989-12-19 | 1994-04-19 | Farmitalia Carlo Erba S.R.L. | Morpholinyl derivatives of doxorubicin and process for their preparation |
| GB2296495B (en) * | 1994-12-23 | 1998-04-15 | Erba Carlo Spa | Anthracycline derivatives |
| US5843903A (en) | 1995-11-27 | 1998-12-01 | The Administrators Of The Tulane Educational Fund | Targeted cytotoxic anthracycline analogs |
-
2000
- 2000-12-19 AT AT00993714T patent/ATE344801T1/de active
- 2000-12-19 EP EP00993714A patent/EP1242438B1/en not_active Expired - Lifetime
- 2000-12-19 JP JP2001550238A patent/JP2003531821A/ja active Pending
- 2000-12-19 ES ES00993714T patent/ES2274823T3/es not_active Expired - Lifetime
- 2000-12-19 PT PT00993714T patent/PT1242438E/pt unknown
- 2000-12-19 DE DE60031793T patent/DE60031793T2/de not_active Expired - Lifetime
- 2000-12-19 AU AU29066/01A patent/AU767394C/en not_active Ceased
- 2000-12-19 CA CA002395660A patent/CA2395660A1/en not_active Abandoned
- 2000-12-19 NZ NZ518764A patent/NZ518764A/en not_active IP Right Cessation
- 2000-12-19 DK DK00993714T patent/DK1242438T3/da active
- 2000-12-19 WO PCT/US2000/033276 patent/WO2001049698A1/en not_active Ceased
- 2000-12-21 US US09/740,991 patent/US6630579B2/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4672057A (en) * | 1985-03-22 | 1987-06-09 | Farmitalia Carlo Erba S.P.A. | Morpholino derivatives of daunorubicin and doxorubicin |
| EP0434960A1 (en) * | 1989-12-19 | 1991-07-03 | PHARMACIA S.p.A. | Chiral 1,5-diiodo-2-methoxy or benzyloxy intermediates |
Also Published As
| Publication number | Publication date |
|---|---|
| NZ518764A (en) | 2004-02-27 |
| PT1242438E (pt) | 2007-02-28 |
| AU767394B2 (en) | 2003-11-06 |
| US6630579B2 (en) | 2003-10-07 |
| DE60031793T2 (de) | 2007-08-23 |
| CA2395660A1 (en) | 2001-07-12 |
| EP1242438A1 (en) | 2002-09-25 |
| AU2906601A (en) | 2001-07-16 |
| US20010036923A1 (en) | 2001-11-01 |
| DK1242438T3 (da) | 2007-02-12 |
| WO2001049698A1 (en) | 2001-07-12 |
| DE60031793D1 (de) | 2006-12-21 |
| EP1242438B1 (en) | 2006-11-08 |
| JP2003531821A (ja) | 2003-10-28 |
| ATE344801T1 (de) | 2006-11-15 |
| ES2274823T3 (es) | 2007-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU767394C (en) | Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use | |
| AU765588C (en) | Cytotoxic agents comprising taxanes and their therapeutic use | |
| US5416064A (en) | Cytotoxic agents comprising maytansinoids and their therapeutic use | |
| CA2485424C (en) | Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE PROPOSED AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 20040924 |